Precision Oncology in Melanoma and Skin Cancer Surgery

Shoshana Levi; Hannah Bank; John Mullinax; Genevieve Boland

doi:10.1016/j.soc.2023.12.017

Precision Oncology in Melanoma and Skin Cancer Surgery

Surg Oncol Clin N Am. 2024 Apr;33(2):369-385. doi: 10.1016/j.soc.2023.12.017. Epub 2024 Jan 9.

Authors

Shoshana Levi¹, Hannah Bank¹, John Mullinax², Genevieve Boland³

Affiliations

¹ Department of Surgery, MGH, Boston, MA, USA.
² Sarcoma Department, Moffitt Cancer Center, Tampa, FL, USA.
³ Department of Surgery, MGH, Boston, MA, USA; Department of Surgery, Massachusetts General Hospital (MGH) Cancer Center, Harvard Medical School (HMS), Boston, MA, USA. Electronic address: GMBOLAND@MGH.HARVARD.EDU.

PMID: 38401915
DOI: 10.1016/j.soc.2023.12.017

Abstract

There has been perhaps no greater advance in the prognosis of solid tumors in the last decade than for patients with metastatic melanoma. This is due to significant improvements in treatment based on two key components of melanoma tumor biology (1) the identification of driver mutations with therapeutic potential and (2) the mechanistic understanding of a tumor-specific immune response. With breakthrough findings in such a relatively short period of time, the treatment of patients with metastatic melanoma has become intensely personalized.

Keywords: Cutaneous oncology; Immunotherapy; Melanoma; Merkel cell carcinoma; Targeted therapy.

Publication types

Review

MeSH terms

Humans
Immunotherapy
Melanoma* / genetics
Melanoma* / surgery
Precision Medicine
Prognosis
Skin Neoplasms* / genetics
Skin Neoplasms* / surgery